Follow-On Biologics Would Save $71 Billion Over 10 Years, Express Scripts Estimates
This article was originally published in The Pink Sheet Daily
Executive Summary
The PBM report models savings stemming from the use of biosimilars for interferons, erythropoietin, growth hormone and insulin.